Insider Selling: Billiontoone (NASDAQ:BLLN) Insider Sells $1,999,800.00 in Stock

Billiontoone, Inc. (NASDAQ:BLLN) insider Thomas Lynch sold 20,000 shares of the stock in a transaction that occurred on Tuesday, September 8th. The shares were sold at an average price of $99.99, for a total transaction of $1,999,800.00. Following the sale, the insider directly owned 700 shares of the company’s stock, valued at $69,993. The trade was a 96.62% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Billiontoone Price Performance

Shares of BLLN opened at $98.77 on Friday. The company has a 50 day moving average of $111.64 and a two-hundred day moving average of $95.81. The company has a quick ratio of 11.31, a current ratio of 11.69 and a debt-to-equity ratio of 0.17. Billiontoone, Inc. has a twelve month low of $61.96 and a twelve month high of $150.44. The company has a market cap of $4.66 billion and a price-to-earnings ratio of 141.10.

Billiontoone (NASDAQ:BLLN) last issued its quarterly earnings results on Wednesday, August 5th. The company reported $0.15 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.15. Billiontoone had a return on equity of 9.96% and a net margin of 8.04%.The business had revenue of $109.45 million for the quarter. As a group, analysts predict that Billiontoone, Inc. will post 0.83 earnings per share for the current fiscal year.

Institutional Trading of Billiontoone

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Rossby Financial LCC acquired a new position in shares of Billiontoone in the fourth quarter valued at about $25,000. Integrated Wealth Concepts LLC purchased a new position in shares of Billiontoone in the second quarter worth about $29,000. MCF Advisors LLC lifted its holdings in shares of Billiontoone by 330.8% during the second quarter. MCF Advisors LLC now owns 448 shares of the company’s stock worth $54,000 after purchasing an additional 344 shares during the period. Wells Fargo & Company MN purchased a new stake in Billiontoone in the fourth quarter valued at approximately $76,000. Finally, Smartleaf Asset Management LLC purchased a new stake in Billiontoone in the fourth quarter valued at approximately $80,000.

Wall Street Analysts Forecast Growth

BLLN has been the subject of a number of research analyst reports. Guggenheim assumed coverage on Billiontoone in a research note on Monday, June 29th. They issued a “buy” rating and a $125.00 price target for the company. JPMorgan Chase & Co. dropped their price target on Billiontoone from $145.00 to $130.00 and set an “overweight” rating on the stock in a research note on Thursday, August 6th. Wall Street Zen lowered shares of Billiontoone from a “buy” rating to a “hold” rating in a research report on Saturday, August 8th. Canaccord Genuity Group started coverage on shares of Billiontoone in a research note on Wednesday, September 2nd. They issued a “buy” rating and a $120.00 target price for the company. Finally, Weiss Ratings raised shares of Billiontoone from a “sell (d)” rating to a “sell (d+)” rating in a research report on Tuesday, June 23rd. Seven research analysts have rated the stock with a Buy rating, two have issued a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $125.88.

About Billiontoone

BillionToOne, Inc is a molecular diagnostics company that develops blood-based tests designed to provide genetic and health information from small amounts of biological material. The company’s technology uses its proprietary quantitative counting template approach to improve the accuracy and sensitivity of molecular testing.

The company’s primary offerings include UNITY, a portfolio of prenatal genetic tests. These services support screening for chromosomal conditions, single-gene disorders and carrier status, and are designed to help healthcare providers assess fetal and maternal genetic risks using a maternal blood sample.